The Use of Platelet-Rich Plasma for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review.
Jun HanFuqiang GaoYajia LiJinhui MaWei SunLijun ShiXinjie WuTengqi LiPublished in: BioMed research international (2020)
PRP treats ONFH mainly through three mechanisms: inducing angiogenesis and osteogenesis to accelerate bone healing, inhibiting inflammatory reactions in necrotic lesions, and preventing apoptosis induced by glucocorticoids. In addition, as an adjunctive therapy for core decompression, the use of PRP is recommended to improve the treatment of early-stage ONFH patients, especially when combined with stem cells and bone grafts, by inducing osteogenic activity and stimulating the differentiation of stem cells in necrotic lesions.
Keyphrases
- platelet rich plasma
- stem cells
- early stage
- newly diagnosed
- end stage renal disease
- bone mineral density
- mesenchymal stem cells
- ejection fraction
- endothelial cells
- signaling pathway
- endoplasmic reticulum stress
- cell therapy
- squamous cell carcinoma
- combination therapy
- cell proliferation
- bone loss
- replacement therapy
- vascular endothelial growth factor
- smoking cessation
- body composition
- rectal cancer